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Background: Few studies consider both the survival and financial benefits of detection of invasive cervical cancer
(ICC) at earlier stages. This study estimated the savings in life-years and costs from early diagnosis of cervical cancer
using an ex post approach.
Methods: A total of 28,797 patients diagnosed with cervical cancer in the period 2002–2009 were identified from
the National Cancer Registry of Taiwan, and linked to the National Mortality Registry until the end of 2011. Life
expectancies (LE) for cancer at different stages were estimated using a semi-parametric extrapolation method. The
expected years of life lost (EYLL) for cancer were calculated by subtracting the LE of the cancer cohort from that of
the age-and sex-matched general population. The mean lifetime costs after diagnosis paid by the single-payer
National Health Insurance during (NHI) 2002–2010 were estimated by multiplying average monthly expenditures by
the survival probabilities and summing up over lifetime.
Results: ICC at stages 1 to 4 had an average EYLL of 6.33 years, 11.64 years, 12.65 years, and 18.61 years,
respectively, while the related lifetime costs paid by the NHI were $7,020, $10,133, $11,120, and $10,015 US dollars,
respectively; the younger the diagnosis age, the higher the savings with regard to EYLL. The mean lifetime costs of
managing cervical cancer were generally lower for the earlier stages compared with stages 3 and 4.
Conclusions: Early detection of ICC saves lives and reduces healthcare costs. These health benefits and monetary
savings can be used for cost-effectiveness assessments and the promotion of regular proactive screening, especially
among older women.
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Cervical cancer is one of the most prevalent types of can-
cer in women, with 530,232 annual cases and 275,008
deaths worldwide in 2008 [1]. Because of widespread
screening programs coupled with advanced medical treat-
ment technologies, women with cervical cancer now have* Correspondence: chengym@mail.ncku.edu.tw; jdwang121@gmail.com
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unless otherwise stated.relatively high five-year survival rates [2-5], and there is a
consensus that early detection of cervical cancer can avoid
premature mortality [3,4]. The Taiwanese government
launched a nationwide cervical screening program in July
1995, in which annual pap smear screenings are offered to
women aged over 30. Recent records from 2009 indicate
that the compliance rate for pap testing in Taiwan is ap-
proximately 50% by age 65, which drops to 30.5% at age
70 or older [6]. If patients with invasive cancer could be
detected at an earlier stage, the potential benefits with re-
gard to the expected years of life lost (EYLL) [7] and
healthcare expenditure would create additional incentives
for cancer screening and treatment. Although there aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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question of how the various stages of cervical cancer at
detection in different age groups influence outcomes in
patient management remains less clear. In this study, the
authors thus used an ex post approach based on national
databases in Taiwan to estimate the life years and health-
care expenditures saved from early detection of cervical
cancer, stratified by both stages and age.
Methods
Study population and datasets
The study commenced after the approval of the Institu-
tional Review Board of National Cheng Kung University
Hospital (NCKUH, IRB number: ER-102-034). A total
of 28,797 patients diagnosed with cervical cancer in
2002–2009 were identified from the National Cancer
Registry of Taiwan [13], which contains data on cancer
staging, diagnosis date and age. The cancer site of inter-
est is the cervix (ICD-9-CM code: 180). Gynecologists
in Taiwan generally follow the clinical staging of FIGO
(International Federation of Gynecology and Obstetrics)
[14], and adopt the treatment guidelines of NCCN (Na-
tional Comprehensive Cancer Network) for invasive cer-
vical cancer [15]. The authors classified cervical cancer
into stage 0 and invasive cancer (stages 1–4).
Survival analysis and extrapolation to estimate life
expectancy and EYLL stratified by stages in different
age groups
All of the above patients were followed until the end of
2011 and linked with the National Mortality Registry to
obtain the survival function via the Kaplan-Meier estima-
tion method. They were further extrapolated to lifetime
based on a semi-parametric method using the age- and
sex-matched referents simulated from the life tables of the
National Vital Statistics of Taiwan, which only requires an
assumption of constant excess hazards [16,17]. The esti-
mates were obtained using iSQoL software [18]. Detailed
methods and mathematical proofs are described in our
previous studies [7-9,16,17]. The average EYLL [7,9] for
patients was calculated by the age- and gender-matched
reference subjects simulated from the hazard functions of
the vital statistics and subtracting the life expectancy of
cancer patients, as shown in Figure 1. Z-tests were also
performed for each group, with a p-value < .05 considered
statistically significant.
Lifetime cost paid by the National Health Insurance (NHI)
stratified by stages in different age groups
This study estimated the lifetime cost by counting the
monthly average dollars reimbursed by the NHI during
2002–2010 for these patients, from the day of validated
diagnosis to the end of life or censored [19,20]. In general,
the NHI comprehensively reimburses all medical servicesfor each cancer patient, including various diagnostic work-
ups and established treatments (e.g. surgery, radiation
therapy, chemotherapy, or management for various com-
plications). When a cancer patient visits a physician, it is
the physician’s responsibility to judge whether the patient’s
specific complaint, and hence the medical services pro-
vided, are related to the diagnosis of his or her underlying
cancer. If so, then the physician can claim for reimburse-
ment on the category of cancer diagnosed, using the Inter-
national Classification of Diseases (9th revision, clinical
modification [ICD9-CM]), which is automatically regis-
tered into the database. The calculation process for the
lifetime costs was as follows: The authors summed the
monthly expenditures for all patients, including the cost
of inpatient, outpatient and emergency care for the treat-
ment of cervical cancer after diagnosis, and divided the ag-
gregate by the number of these patients who were still
alive during each month to estimate the monthly average
costs to the NHI. Annual NHI expenditures were first ad-
justed to the 2010 Consumer Price Index (CPI) [21] and
exchange rate (1USD = 29.322 TWDs), followed by apply-
ing a 3% annual discount rate [21,22]. The monetary value
after the end of the follow-up period was assumed to be
the same as the average of the last 10% of measurements
through smoothing to extrapolate lifetime. The total aver-
age monthly expenditures were multiplied by the monthly
survival probabilities for each stage and age group over
the course of a lifetime, and all these monetary values
were summed to obtain the lifetime healthcare expend-
iture for each group. Z-tests were also performed, with a
p-value < .05 considered statistically significant.
Uncertainties, sensitivity analysis and validation of the
extrapolation method
This study used an ex post approach instead of the con-
ventional ex ante one. Our survival data were real follow-
up data for over 10 years, and the healthcare expenditures
were directly retrieved from the reimbursement data files
of the NHI, plus adjustment for the 2010 CPI. The authors
also calculated the standard errors of the means by the
bootstrap method for 100 repeated samples in these pa-
rameters, as stratified by age groups and stages, including
life expectancy and EYLL, with a 95% confidence interval
for lifetime healthcare expenditures.
In order to validate the extrapolation method, the au-
thors selected sub-cohorts of patients with cervical cancer
between 2002 and 2006, and then extrapolated these re-
sults to the end of 2011, and the results were compared
with the Kaplan-Meier (K-M) estimates of the actual
follow-ups. Assuming that the K-M estimates are the gold
standard, this study calculated the relative biases for sub-
cohorts with cervical cancer. The relative bias (RB) is
defined as follows: RB = (estimate from extrapolation – K-
M estimate)/K-M estimate.
Figure 1 Average expected years of life lost (EYLL) due to cervical cancer stratified by stages. The difference (shadowed area) of LE between the
cohort of cervical cancer and age-, gender-matched reference population, which represents the average EYLL of developing a case of cervical cancer.
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Cervical cancer at stages 1 to 4 had an average EYLL of
6.33 years, 11.64 years, 12.65 years, and 18.61 years, re-
spectively; the differences among different stages were all
statistically significant (z-tests, all p’s < 0.001), as shown on
Table 1 and Figure 1. The mean lifetime costs of managing
stage 0 (US $1,316) were found to be significantly lower
than those of stages 1–4 of invasive cancer (US $7,020,
$10,133, $11,120 and $10,015, respectively). The younger
the age of diagnosis, the higher the EYLL (Table 1), and, in
general, the earlier the stage of diagnosis, the smaller the
lifetime expenditures paid by the NHI. In addition, detec-
tion of invasive cervical cancer before stage 3 comparedTable 1 Life expectancy, expected years of life lost, and lifetim
Age Stage Case number Mean age at diagnosis (SD)* LE
All 1-4 11,096 56.46 (14.3) 19
<50 yrs, 0 10,920 38.8 (6.6) 43
1 2,865 41.5 (5.6) 30
2 737 43.3 (5.1) 19
3 248 43.3 (5.4) 17
4 170 42.9 (5.7) 6.5
50-64 yrs 0 3,923 55.9 (4.4) 27
1 2,065 55.7 (4.3) 23
2 1,037 56.3 (4.3) 18
3 386 56.0 (4.3) 12
4 248 56.3 (4.5) 5.6
≥65 yrs 0 2,858 72.1 (5.7) 14
1 1,306 72.9 (6.5) 12
2 1,213 74.8 (6.8) 9.0
3 523 76.4 (7.4) 5.1
4 298 76.5 (7.4) 2.8
*SD, standard deviation; †SE, standard error of mean; LE, Life expectancy, in years; Ewith a more advanced stage can save life-years and costs
for patients aged under 65, while those aged over 65 must
be detected earlier than stage 2 to see a consistent trend
with regard to these benefits (Table 1). The results ob-
tained to validate our semi-parametric method for esti-
mating lifetime survival show that the relative biases of
extrapolation from the end of the 5th year to that of the
10th year were all below 4%, except for stage 4, due to the
small sample size (Table 2). Since all values of the relative
biases are negative, they indicate a trend of underestima-
tion of lifetime survival for cervical cancer based on this
method. The absolute magnitudes of such biases, however,
range from 0.07 to 0.26 years, or less than 3 months. Ine expenditures (USD) of cervical cancer
(SE)† EYLL (SE)† Lifetime healthcare expenditures (95% CI‡)
.85 (0.04) 7.78 (0.03) 8,542 (5,397-11,878)
.47 (0.04) - 1,087 (519–1,778)
.01 (0.07) 10.57 (0.06) 6,915 (4,118-9,304)
.10 (0.15) 19.86 (0.15) 11,955 (8,370-16,649)
.61 (0.23) 21.31 (0.24) 14,832 (9,755-20,478)
5 (0.17) 32.78 (0.18) 12,069 (9,495-15,138)
.44 (0.03) - 1,665 (1,029-2,552)
.77 (0.06) 3.78 (0.05) 7,629 (4,759-11,766)
.51 (0.12) 8.60 (0.12) 10,599 (6,200-15,784)
.37 (0.18) 14.94 (0.18) 13,411 (9,544-18,177)
5 (0.20) 21.43 (0.21) 12,659 (9,494-16,254)
.28 (0.02) - 1,725 (953–2,727)
.36 (0.05) 1.37 (0.05) 6,297 (3,518-9,984)
2 (0.07) 3.51 (0.06) 8,511 (4,438-12,040)
5 (0.12) 6.38 (0.12) 8,136 (4,633-10,437)
3 (0.16) 8.61 (0.16) 6,995 (4,548-9,701)
YLL, expected years of life lost; ‡CI, confidence interval.
Table 2 Validation of relative bias of five-year extrapolation based on actual 10-year survival using Kaplan-Meier (K-M)
estimates as the gold standard
Stage Cohort size Mean age at
diagnosis (SD)*
Censored rate (%) 10-year survival based on
K-M estimate in years (SE)†
Extrapolation based on the first
five-year follow up in years (SE)†
Relative bias (%)
1 3,823 52.49 (13.20) 92.68 8.60 (0.05) 8.47 (0.02) −1.57
2 1,791 60.39 (13.99) 80.07 6.76 (0.10) 6.69 (0.05) −1.05
3 680 61.65 (14.91) 58.38 4.69 (0.15) 4.53 (0.08) −3.57
4 373 60.40 (14.69) 39.68 2.71 (0.15) 2.45 (0.10) −9.54
*SD, standard deviation; †SE, standard error of mean.
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0.84, 0.63, 0.39 and 0.18 for stages from 0 to 4, respectively
(Figure 2).
Discussion
This study is the first that simultaneously documents
the improvements in life expectancy, EYLL, and savings
in lifetime healthcare expenditures at different stages of
cervical cancer, and the results show that in addition to
stage 0, detection of cervical cancer at stages 1–3 can
lead to more improvements in life expectancy and costs
compared with a more advanced stage (Table 1), and the
younger the age of diagnosis, the greater the benefits
with regard to EYLL. However, we must carefully exam-
ine the accuracy of our estimation before making further
inferences. First, since we only included patients with
cervical cancer that had been verified with histopatho-
logical evidence and registered in the Taiwan Cancer
Registry, the diagnoses were highly accurate. Second, be-
cause all cases of invasive cervical cancer are registered
in the Catastrophic Illnesses database, the waiving of all
co-payments has been under the careful monitoring and
control of gyneco-oncologists, and all related reimburse-
ments for treating cervical cancer would generally follow
the established guidelines, being comprehensive and
comparable for different stages. Third, all the extrapola-
tions of survival functions are based on the validatedFigure 2 Survival probability of cervical cancer stratified by
stages. Their five-year survival probabilities were 0.96, 0.84, 0.63, 0.39
and 0.18 in different stages from stages 0 to 4, respectively.assumption of “constant excess hazard”, which can be ob-
tained by showing a straight line after taking the logit
transform of the survival ratio between the index and age-
and gender-matched referents [16,17]. As the assumption
of a constant excess hazard may have a strong impact on
the estimation of life expectancy for cervical cancer, we
conduct a sensitivity analysis. Because the iSQoL software
cannot be directly set to zero value of slope for extrapola-
tion, we deliberately chose the second slope value that is
closest to zero (either negative or positive) for extrapola-
tion 10 years after follow-up. The results (presented in the
Additional file 1) show that all the life expectancies were
very close (<15% difference), indicating that our estimates
are relatively accurate. Moreover, this study validated this
estimation by extrapolating the survival of the first five to
10 years, and the results showed that this approach usually
has less than 10% error in comparison with the actual sur-
vival based on the Kaplan-Meier method (Table 2). In one
of our previous studies [7], we employed the cohort of cer-
vical cancer patients between 1990 and 2001 in the
National Cancer Registry and followed up to 2004, while
the current study enrolled the cohort of 2002–2009 and
followed up to 2011. Since there have been no major
changes with regard to treating cervical cancer during the
last two decades, it is perhaps not surprising that we found
no major changes in the estimates of life expectancy be-
tween the two cohorts (19.77 years in Chu’s study versus
19.85 years in this work). However, as the life expectancy
of the general female population has increased from
77.7 yrs in 1995 to 80.8 yrs in 2005, it is not unexpected
that the EYLL also increased from 6.33 years to 7.78 years.
Therefore, the estimation method can be seen as both
consistent and accurate, and, as noted above, we tenta-
tively conclude that detection of invasive cervical cancer
before stage 3 compared with a more advanced stage can
have benefits with regard to life-years and costs for pa-
tients aged below 65, while those aged over 65 must be de-
tected earlier than stage 2 to see the same benefits.
Generally speaking, the earlier the stage at diagnosis, the
better the outcomes, although we might have over-
estimated the effects of early detection because of poten-
tial length time bias.
Studies of cervical cancer screening tend to emphasize
detection at stage 0. This study, however, provides solid
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vical cancer at stage 1 or 2 is also very worthwhile. The
calculation of EYLL in Table 1 used an age- and gender-
matched general population as referents, and provides
estimates for the number of life-years lost due to inva-
sive cancer [9,12]. Because our method takes the age at
diagnosis into consideration, the estimations would be
less affected by lead time bias and more accurate than
direct comparisons of life expectancies for cancer pa-
tients diagnosed at different stages. We recommend that
the results be used to analyze the cost-effectiveness of
screening programs. As Figure 2 indicates that the cer-
vical cancer survival probabilities in Taiwan appear com-
parable with those reported from other countries [2-5],
our findings may also be applicable to them.
Limitations
Although this study has used the most comprehensive
national data currently available in Taiwan, it has the fol-
lowing limitations that need to be addressed: First, the
lifetime extrapolation is based on current and prior ex-
periences, especially the national life tables; however, it
is clear that such an ex post approach could easily
underestimate the actual survival of future cancer popu-
lations, because it cannot predict the future development
and adoption of newer technologies for cancer diagnosis
and management. Therefore, our estimation of the life-
time survival of cancer patients may be a conservative
one, while the EYLL might be overestimated. Second, be-
cause life expectancy is also a function of co-morbidity,
performance states, and recurrence [23], the current esti-
mates provide only a crude estimation of the average
EYLL. Future studies with a larger cohort may stratify
them into sub-cohorts based on more clinical data on co-
morbidities, performance states, and recurrence, to im-
prove the accuracy of the predictions. Third, we did not
consider the growing evidence that those women who de-
cide not to participate in screening may be inherently dif-
ferent from those who decide to participate, and these
non-participants might have higher other-cause mortality
[24]. If this phenomena occurred in Taiwan, then our
EYLL would be overestimated. Fourth, this study adopted
the insurer’s perspective, and only direct medical costs
were estimated. Because of the lack of empirical data on
the costs of out-of-pocket money or lost productivity due
to cervical cancer or premature death, our results under-
estimate the cost of illness to the whole society. Finally,
because the healthcare expenditures after the end of the
follow-up period were assumed to be the same as the aver-
age of the last 10% of measurements based on kernel
smoothing, this study might have overestimated the costs
after the end of 10 years of follow-up. However, since
almost all cases of cervical cancer would be in healthy con-
dition 5–10 years after diagnosis, except those approachingthe end of their lives, the average costs due to cervical
cancer would generally become smaller given a large num-
ber of healthy survivors and higher cumulative discount
rates. The potential overestimation due to this would thus
be very small.
Policy implications for community healthcare
Pap smears are not very popular among women aged 60
and older in Taiwan, which might have resulted in
higher morbidity and mortality rates for cervical cancer
among this group [25]. This study provides evidence that
early detection of invasive cancer can saves lives and re-
duce costs for both young and old patients, and that the
earlier detection occurs, the better (Table 1), and these
facts can be used to encourage those who are otherwise
afraid of undergoing cancer screening. However, further
evaluations of the cost-effectiveness of this approach are
needed in order to optimize the utilization of resources.
Conclusion
Early detection of cervical cancer can save people and re-
duce costs for the NHI, and details of these benefits can be
used to encourage regular proactive screening, especially
among women older than 60, who currently are less likely
to receive a pap smear in Taiwan. The prospective health
benefits for patients with stages 1–3 of invasive cancer,
compared to those with more advanced stages, should thus
be clearly explained. The authors also recommend future
studies consider evaluating the cost-effectiveness of differ-
ent prevention programs, in which the likelihood of certain
events (e.g., incident rates and rate ratios) can be integrated
with health outcomes to improve the efficiency and fairness
of the related health policies.Additional file
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